nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—osteoporosis	0.416	1	CbGaD
Pomalidomide—PTGS2—Risedronate—osteoporosis	0.135	0.364	CbGbCtD
Pomalidomide—CYP1A2—Estropipate—osteoporosis	0.0386	0.104	CbGbCtD
Pomalidomide—ABCB1—Ethinyl Estradiol—osteoporosis	0.0217	0.0586	CbGbCtD
Pomalidomide—CYP3A4—Estropipate—osteoporosis	0.0202	0.0545	CbGbCtD
Pomalidomide—CYP3A4—Calcitriol—osteoporosis	0.0202	0.0545	CbGbCtD
Pomalidomide—CYP1A2—Conjugated Estrogens—osteoporosis	0.0183	0.0492	CbGbCtD
Pomalidomide—CYP3A4—Ergocalciferol—osteoporosis	0.0162	0.0436	CbGbCtD
Pomalidomide—CYP1A2—Estradiol—osteoporosis	0.016	0.0432	CbGbCtD
Pomalidomide—ABCB1—Conjugated Estrogens—osteoporosis	0.016	0.043	CbGbCtD
Pomalidomide—ABCB1—Estradiol—osteoporosis	0.014	0.0378	CbGbCtD
Pomalidomide—CYP3A4—Raloxifene—osteoporosis	0.0135	0.0364	CbGbCtD
Pomalidomide—CYP3A4—Ethinyl Estradiol—osteoporosis	0.013	0.0351	CbGbCtD
Pomalidomide—CYP3A4—Cholecalciferol—osteoporosis	0.0104	0.0281	CbGbCtD
Pomalidomide—CYP3A4—Conjugated Estrogens—osteoporosis	0.00956	0.0258	CbGbCtD
Pomalidomide—CYP3A4—Estradiol—osteoporosis	0.0084	0.0226	CbGbCtD
Pomalidomide—Lenalidomide—TNFSF11—osteoporosis	0.00559	0.891	CrCbGaD
Pomalidomide—Thalidomide—TNF—osteoporosis	0.000685	0.109	CrCbGaD
Pomalidomide—Leukopenia—Pamidronate—osteoporosis	0.000188	0.00113	CcSEcCtD
Pomalidomide—Anxiety—Risedronate—osteoporosis	0.000188	0.00113	CcSEcCtD
Pomalidomide—Pain—Ibandronate—osteoporosis	0.000187	0.00113	CcSEcCtD
Pomalidomide—Constipation—Ibandronate—osteoporosis	0.000187	0.00113	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000187	0.00113	CcSEcCtD
Pomalidomide—Pruritus—Etidronic acid—osteoporosis	0.000187	0.00112	CcSEcCtD
Pomalidomide—Decreased appetite—Calcitriol—osteoporosis	0.000186	0.00112	CcSEcCtD
Pomalidomide—Mental disorder—Conjugated Estrogens—osteoporosis	0.000186	0.00112	CcSEcCtD
Pomalidomide—Back pain—Zoledronate—osteoporosis	0.000186	0.00112	CcSEcCtD
Pomalidomide—Neuropathy peripheral—Estradiol—osteoporosis	0.000186	0.00112	CcSEcCtD
Pomalidomide—Feeling abnormal—Alendronate—osteoporosis	0.000185	0.00112	CcSEcCtD
Pomalidomide—Malnutrition—Conjugated Estrogens—osteoporosis	0.000185	0.00111	CcSEcCtD
Pomalidomide—Muscle spasms—Zoledronate—osteoporosis	0.000185	0.00111	CcSEcCtD
Pomalidomide—Urinary tract infection—Estradiol—osteoporosis	0.000184	0.00111	CcSEcCtD
Pomalidomide—Infection—Ethinyl Estradiol—osteoporosis	0.000184	0.00111	CcSEcCtD
Pomalidomide—Cough—Pamidronate—osteoporosis	0.000183	0.0011	CcSEcCtD
Pomalidomide—Pain—Calcitriol—osteoporosis	0.000183	0.0011	CcSEcCtD
Pomalidomide—Constipation—Calcitriol—osteoporosis	0.000183	0.0011	CcSEcCtD
Pomalidomide—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000181	0.00109	CcSEcCtD
Pomalidomide—Diarrhoea—Etidronic acid—osteoporosis	0.000181	0.00109	CcSEcCtD
Pomalidomide—Body temperature increased—Estropipate—osteoporosis	0.00018	0.00109	CcSEcCtD
Pomalidomide—Feeling abnormal—Ibandronate—osteoporosis	0.00018	0.00109	CcSEcCtD
Pomalidomide—Tremor—Zoledronate—osteoporosis	0.00018	0.00108	CcSEcCtD
Pomalidomide—Skin disorder—Ethinyl Estradiol—osteoporosis	0.00018	0.00108	CcSEcCtD
Pomalidomide—Infection—Risedronate—osteoporosis	0.000179	0.00108	CcSEcCtD
Pomalidomide—Hepatobiliary disease—Estradiol—osteoporosis	0.000179	0.00108	CcSEcCtD
Pomalidomide—Arthralgia—Pamidronate—osteoporosis	0.000179	0.00108	CcSEcCtD
Pomalidomide—Back pain—Conjugated Estrogens—osteoporosis	0.000179	0.00108	CcSEcCtD
Pomalidomide—Epistaxis—Estradiol—osteoporosis	0.000179	0.00108	CcSEcCtD
Pomalidomide—Anxiety—Pamidronate—osteoporosis	0.000178	0.00107	CcSEcCtD
Pomalidomide—Body temperature increased—Alendronate—osteoporosis	0.000178	0.00107	CcSEcCtD
Pomalidomide—Muscle spasms—Conjugated Estrogens—osteoporosis	0.000178	0.00107	CcSEcCtD
Pomalidomide—Anaemia—Zoledronate—osteoporosis	0.000177	0.00107	CcSEcCtD
Pomalidomide—Nervous system disorder—Risedronate—osteoporosis	0.000177	0.00107	CcSEcCtD
Pomalidomide—Skin disorder—Risedronate—osteoporosis	0.000175	0.00106	CcSEcCtD
Pomalidomide—Body temperature increased—Raloxifene—osteoporosis	0.000175	0.00105	CcSEcCtD
Pomalidomide—Body temperature increased—Ibandronate—osteoporosis	0.000173	0.00104	CcSEcCtD
Pomalidomide—Confusional state—Pamidronate—osteoporosis	0.000173	0.00104	CcSEcCtD
Pomalidomide—Vertigo—Zoledronate—osteoporosis	0.000172	0.00104	CcSEcCtD
Pomalidomide—Leukopenia—Zoledronate—osteoporosis	0.000172	0.00103	CcSEcCtD
Pomalidomide—Infection—Pamidronate—osteoporosis	0.00017	0.00103	CcSEcCtD
Pomalidomide—Body temperature increased—Calcitriol—osteoporosis	0.000169	0.00102	CcSEcCtD
Pomalidomide—Hypersensitivity—Estropipate—osteoporosis	0.000168	0.00101	CcSEcCtD
Pomalidomide—Nervous system disorder—Pamidronate—osteoporosis	0.000168	0.00101	CcSEcCtD
Pomalidomide—Thrombocytopenia—Pamidronate—osteoporosis	0.000168	0.00101	CcSEcCtD
Pomalidomide—Urinary tract disorder—Estradiol—osteoporosis	0.000168	0.00101	CcSEcCtD
Pomalidomide—Vomiting—Etidronic acid—osteoporosis	0.000168	0.00101	CcSEcCtD
Pomalidomide—Cough—Zoledronate—osteoporosis	0.000167	0.00101	CcSEcCtD
Pomalidomide—Oedema peripheral—Estradiol—osteoporosis	0.000167	0.00101	CcSEcCtD
Pomalidomide—Connective tissue disorder—Estradiol—osteoporosis	0.000167	0.00101	CcSEcCtD
Pomalidomide—Urethral disorder—Estradiol—osteoporosis	0.000167	0.001	CcSEcCtD
Pomalidomide—Rash—Etidronic acid—osteoporosis	0.000166	0.001	CcSEcCtD
Pomalidomide—Dermatitis—Etidronic acid—osteoporosis	0.000166	0.001	CcSEcCtD
Pomalidomide—Vertigo—Conjugated Estrogens—osteoporosis	0.000166	0.001	CcSEcCtD
Pomalidomide—Hyperhidrosis—Pamidronate—osteoporosis	0.000166	0.000999	CcSEcCtD
Pomalidomide—Hypersensitivity—Alendronate—osteoporosis	0.000166	0.000998	CcSEcCtD
Pomalidomide—Headache—Etidronic acid—osteoporosis	0.000165	0.000996	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Risedronate—osteoporosis	0.000164	0.00099	CcSEcCtD
Pomalidomide—Asthenia—Estropipate—osteoporosis	0.000164	0.000987	CcSEcCtD
Pomalidomide—Arthralgia—Zoledronate—osteoporosis	0.000163	0.000984	CcSEcCtD
Pomalidomide—Insomnia—Risedronate—osteoporosis	0.000163	0.000983	CcSEcCtD
Pomalidomide—Anxiety—Zoledronate—osteoporosis	0.000163	0.000981	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000162	0.000978	CcSEcCtD
Pomalidomide—Pruritus—Estropipate—osteoporosis	0.000162	0.000973	CcSEcCtD
Pomalidomide—Asthenia—Alendronate—osteoporosis	0.000161	0.000972	CcSEcCtD
Pomalidomide—Hypersensitivity—Ibandronate—osteoporosis	0.000161	0.000971	CcSEcCtD
Pomalidomide—Cough—Conjugated Estrogens—osteoporosis	0.000161	0.000971	CcSEcCtD
Pomalidomide—Dyspnoea—Risedronate—osteoporosis	0.000161	0.000969	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.00016	0.000962	CcSEcCtD
Pomalidomide—Fatigue—Ethinyl Estradiol—osteoporosis	0.00016	0.000961	CcSEcCtD
Pomalidomide—Pruritus—Alendronate—osteoporosis	0.000159	0.000958	CcSEcCtD
Pomalidomide—Constipation—Ethinyl Estradiol—osteoporosis	0.000158	0.000953	CcSEcCtD
Pomalidomide—Confusional state—Zoledronate—osteoporosis	0.000158	0.000951	CcSEcCtD
Pomalidomide—Hypersensitivity—Calcitriol—osteoporosis	0.000158	0.000951	CcSEcCtD
Pomalidomide—Cardiac disorder—Estradiol—osteoporosis	0.000158	0.00095	CcSEcCtD
Pomalidomide—Arthralgia—Conjugated Estrogens—osteoporosis	0.000157	0.000948	CcSEcCtD
Pomalidomide—Asthenia—Ibandronate—osteoporosis	0.000157	0.000946	CcSEcCtD
Pomalidomide—Anxiety—Conjugated Estrogens—osteoporosis	0.000157	0.000944	CcSEcCtD
Pomalidomide—Nausea—Etidronic acid—osteoporosis	0.000157	0.000944	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000156	0.000941	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Pamidronate—osteoporosis	0.000156	0.000941	CcSEcCtD
Pomalidomide—Diarrhoea—Estropipate—osteoporosis	0.000156	0.000941	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Risedronate—osteoporosis	0.000156	0.000938	CcSEcCtD
Pomalidomide—Infection—Zoledronate—osteoporosis	0.000156	0.000937	CcSEcCtD
Pomalidomide—Fatigue—Risedronate—osteoporosis	0.000156	0.000937	CcSEcCtD
Pomalidomide—Insomnia—Pamidronate—osteoporosis	0.000155	0.000934	CcSEcCtD
Pomalidomide—Pruritus—Ibandronate—osteoporosis	0.000155	0.000933	CcSEcCtD
Pomalidomide—Pain—Risedronate—osteoporosis	0.000154	0.000929	CcSEcCtD
Pomalidomide—Constipation—Risedronate—osteoporosis	0.000154	0.000929	CcSEcCtD
Pomalidomide—Angiopathy—Estradiol—osteoporosis	0.000154	0.000929	CcSEcCtD
Pomalidomide—Diarrhoea—Alendronate—osteoporosis	0.000154	0.000927	CcSEcCtD
Pomalidomide—Asthenia—Calcitriol—osteoporosis	0.000154	0.000926	CcSEcCtD
Pomalidomide—Nervous system disorder—Zoledronate—osteoporosis	0.000154	0.000925	CcSEcCtD
Pomalidomide—Thrombocytopenia—Zoledronate—osteoporosis	0.000153	0.000924	CcSEcCtD
Pomalidomide—Mediastinal disorder—Estradiol—osteoporosis	0.000153	0.000922	CcSEcCtD
Pomalidomide—Dyspnoea—Pamidronate—osteoporosis	0.000153	0.000921	CcSEcCtD
Pomalidomide—Feeling abnormal—Ethinyl Estradiol—osteoporosis	0.000152	0.000918	CcSEcCtD
Pomalidomide—Chills—Estradiol—osteoporosis	0.000152	0.000918	CcSEcCtD
Pomalidomide—Skin disorder—Zoledronate—osteoporosis	0.000152	0.000917	CcSEcCtD
Pomalidomide—Pruritus—Calcitriol—osteoporosis	0.000152	0.000913	CcSEcCtD
Pomalidomide—Hyperhidrosis—Zoledronate—osteoporosis	0.000151	0.000912	CcSEcCtD
Pomalidomide—Diarrhoea—Raloxifene—osteoporosis	0.000151	0.000911	CcSEcCtD
Pomalidomide—Dizziness—Estropipate—osteoporosis	0.000151	0.000909	CcSEcCtD
Pomalidomide—Infection—Conjugated Estrogens—osteoporosis	0.00015	0.000903	CcSEcCtD
Pomalidomide—Diarrhoea—Ibandronate—osteoporosis	0.00015	0.000902	CcSEcCtD
Pomalidomide—Decreased appetite—Pamidronate—osteoporosis	0.000149	0.000898	CcSEcCtD
Pomalidomide—Mental disorder—Estradiol—osteoporosis	0.000149	0.000897	CcSEcCtD
Pomalidomide—Dizziness—Alendronate—osteoporosis	0.000149	0.000896	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000148	0.000892	CcSEcCtD
Pomalidomide—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000148	0.000891	CcSEcCtD
Pomalidomide—Malnutrition—Estradiol—osteoporosis	0.000148	0.000891	CcSEcCtD
Pomalidomide—Fatigue—Pamidronate—osteoporosis	0.000148	0.000891	CcSEcCtD
Pomalidomide—Pain—Pamidronate—osteoporosis	0.000147	0.000883	CcSEcCtD
Pomalidomide—Constipation—Pamidronate—osteoporosis	0.000147	0.000883	CcSEcCtD
Pomalidomide—Diarrhoea—Calcitriol—osteoporosis	0.000147	0.000883	CcSEcCtD
Pomalidomide—Skin disorder—Conjugated Estrogens—osteoporosis	0.000147	0.000883	CcSEcCtD
Pomalidomide—Body temperature increased—Ethinyl Estradiol—osteoporosis	0.000146	0.000881	CcSEcCtD
Pomalidomide—Dizziness—Raloxifene—osteoporosis	0.000146	0.000881	CcSEcCtD
Pomalidomide—Hyperhidrosis—Conjugated Estrogens—osteoporosis	0.000146	0.000878	CcSEcCtD
Pomalidomide—Vomiting—Estropipate—osteoporosis	0.000145	0.000874	CcSEcCtD
Pomalidomide—Dizziness—Ibandronate—osteoporosis	0.000145	0.000872	CcSEcCtD
Pomalidomide—Rash—Estropipate—osteoporosis	0.000144	0.000867	CcSEcCtD
Pomalidomide—Dermatitis—Estropipate—osteoporosis	0.000144	0.000866	CcSEcCtD
Pomalidomide—Back pain—Estradiol—osteoporosis	0.000143	0.000862	CcSEcCtD
Pomalidomide—Headache—Estropipate—osteoporosis	0.000143	0.000861	CcSEcCtD
Pomalidomide—Vomiting—Alendronate—osteoporosis	0.000143	0.000861	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Zoledronate—osteoporosis	0.000143	0.00086	CcSEcCtD
Pomalidomide—Body temperature increased—Risedronate—osteoporosis	0.000143	0.000859	CcSEcCtD
Pomalidomide—Muscle spasms—Estradiol—osteoporosis	0.000142	0.000857	CcSEcCtD
Pomalidomide—Rash—Alendronate—osteoporosis	0.000142	0.000854	CcSEcCtD
Pomalidomide—Insomnia—Zoledronate—osteoporosis	0.000142	0.000853	CcSEcCtD
Pomalidomide—Dermatitis—Alendronate—osteoporosis	0.000142	0.000853	CcSEcCtD
Pomalidomide—Feeling abnormal—Pamidronate—osteoporosis	0.000141	0.000851	CcSEcCtD
Pomalidomide—Headache—Alendronate—osteoporosis	0.000141	0.000848	CcSEcCtD
Pomalidomide—Vomiting—Raloxifene—osteoporosis	0.000141	0.000847	CcSEcCtD
Pomalidomide—Dyspnoea—Zoledronate—osteoporosis	0.00014	0.000841	CcSEcCtD
Pomalidomide—Rash—Raloxifene—osteoporosis	0.000139	0.00084	CcSEcCtD
Pomalidomide—Dermatitis—Raloxifene—osteoporosis	0.000139	0.000839	CcSEcCtD
Pomalidomide—Vomiting—Ibandronate—osteoporosis	0.000139	0.000838	CcSEcCtD
Pomalidomide—Tremor—Estradiol—osteoporosis	0.000139	0.000835	CcSEcCtD
Pomalidomide—Headache—Raloxifene—osteoporosis	0.000139	0.000834	CcSEcCtD
Pomalidomide—Rash—Ibandronate—osteoporosis	0.000138	0.000831	CcSEcCtD
Pomalidomide—Dermatitis—Ibandronate—osteoporosis	0.000138	0.000831	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Conjugated Estrogens—osteoporosis	0.000137	0.000828	CcSEcCtD
Pomalidomide—Headache—Ibandronate—osteoporosis	0.000137	0.000826	CcSEcCtD
Pomalidomide—Insomnia—Conjugated Estrogens—osteoporosis	0.000136	0.000822	CcSEcCtD
Pomalidomide—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000136	0.000821	CcSEcCtD
Pomalidomide—Vomiting—Calcitriol—osteoporosis	0.000136	0.000821	CcSEcCtD
Pomalidomide—Decreased appetite—Zoledronate—osteoporosis	0.000136	0.00082	CcSEcCtD
Pomalidomide—Nausea—Estropipate—osteoporosis	0.000136	0.000817	CcSEcCtD
Pomalidomide—Body temperature increased—Pamidronate—osteoporosis	0.000136	0.000817	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Zoledronate—osteoporosis	0.000135	0.000815	CcSEcCtD
Pomalidomide—Rash—Calcitriol—osteoporosis	0.000135	0.000814	CcSEcCtD
Pomalidomide—Fatigue—Zoledronate—osteoporosis	0.000135	0.000814	CcSEcCtD
Pomalidomide—Dermatitis—Calcitriol—osteoporosis	0.000135	0.000813	CcSEcCtD
Pomalidomide—Dyspnoea—Conjugated Estrogens—osteoporosis	0.000134	0.00081	CcSEcCtD
Pomalidomide—Headache—Calcitriol—osteoporosis	0.000134	0.000809	CcSEcCtD
Pomalidomide—Pain—Zoledronate—osteoporosis	0.000134	0.000807	CcSEcCtD
Pomalidomide—Constipation—Zoledronate—osteoporosis	0.000134	0.000807	CcSEcCtD
Pomalidomide—Nausea—Alendronate—osteoporosis	0.000134	0.000804	CcSEcCtD
Pomalidomide—Hypersensitivity—Risedronate—osteoporosis	0.000133	0.000801	CcSEcCtD
Pomalidomide—Vertigo—Estradiol—osteoporosis	0.000133	0.0008	CcSEcCtD
Pomalidomide—Asthenia—Ethinyl Estradiol—osteoporosis	0.000133	0.0008	CcSEcCtD
Pomalidomide—Nausea—Raloxifene—osteoporosis	0.000131	0.000791	CcSEcCtD
Pomalidomide—Decreased appetite—Conjugated Estrogens—osteoporosis	0.000131	0.00079	CcSEcCtD
Pomalidomide—Pruritus—Ethinyl Estradiol—osteoporosis	0.000131	0.000789	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.00013	0.000784	CcSEcCtD
Pomalidomide—Fatigue—Conjugated Estrogens—osteoporosis	0.00013	0.000783	CcSEcCtD
Pomalidomide—Nausea—Ibandronate—osteoporosis	0.00013	0.000783	CcSEcCtD
Pomalidomide—Asthenia—Risedronate—osteoporosis	0.000129	0.00078	CcSEcCtD
Pomalidomide—Feeling abnormal—Zoledronate—osteoporosis	0.000129	0.000778	CcSEcCtD
Pomalidomide—Cough—Estradiol—osteoporosis	0.000129	0.000777	CcSEcCtD
Pomalidomide—Constipation—Conjugated Estrogens—osteoporosis	0.000129	0.000777	CcSEcCtD
Pomalidomide—Pain—Conjugated Estrogens—osteoporosis	0.000129	0.000777	CcSEcCtD
Pomalidomide—Pruritus—Risedronate—osteoporosis	0.000128	0.000769	CcSEcCtD
Pomalidomide—Nausea—Calcitriol—osteoporosis	0.000127	0.000767	CcSEcCtD
Pomalidomide—Diarrhoea—Ethinyl Estradiol—osteoporosis	0.000127	0.000763	CcSEcCtD
Pomalidomide—Hypersensitivity—Pamidronate—osteoporosis	0.000126	0.000761	CcSEcCtD
Pomalidomide—Arthralgia—Estradiol—osteoporosis	0.000126	0.000759	CcSEcCtD
Pomalidomide—Anxiety—Estradiol—osteoporosis	0.000125	0.000756	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000125	0.000753	CcSEcCtD
Pomalidomide—Body temperature increased—Zoledronate—osteoporosis	0.000124	0.000746	CcSEcCtD
Pomalidomide—Diarrhoea—Risedronate—osteoporosis	0.000123	0.000744	CcSEcCtD
Pomalidomide—Asthenia—Pamidronate—osteoporosis	0.000123	0.000741	CcSEcCtD
Pomalidomide—Dizziness—Ethinyl Estradiol—osteoporosis	0.000122	0.000737	CcSEcCtD
Pomalidomide—Confusional state—Estradiol—osteoporosis	0.000122	0.000733	CcSEcCtD
Pomalidomide—Pruritus—Pamidronate—osteoporosis	0.000121	0.000731	CcSEcCtD
Pomalidomide—Infection—Estradiol—osteoporosis	0.00012	0.000722	CcSEcCtD
Pomalidomide—Dizziness—Risedronate—osteoporosis	0.000119	0.000719	CcSEcCtD
Pomalidomide—Body temperature increased—Conjugated Estrogens—osteoporosis	0.000119	0.000718	CcSEcCtD
Pomalidomide—Nervous system disorder—Estradiol—osteoporosis	0.000118	0.000713	CcSEcCtD
Pomalidomide—Vomiting—Ethinyl Estradiol—osteoporosis	0.000118	0.000709	CcSEcCtD
Pomalidomide—Diarrhoea—Pamidronate—osteoporosis	0.000117	0.000707	CcSEcCtD
Pomalidomide—Skin disorder—Estradiol—osteoporosis	0.000117	0.000706	CcSEcCtD
Pomalidomide—Hyperhidrosis—Estradiol—osteoporosis	0.000117	0.000703	CcSEcCtD
Pomalidomide—Rash—Ethinyl Estradiol—osteoporosis	0.000117	0.000703	CcSEcCtD
Pomalidomide—Dermatitis—Ethinyl Estradiol—osteoporosis	0.000117	0.000702	CcSEcCtD
Pomalidomide—Headache—Ethinyl Estradiol—osteoporosis	0.000116	0.000698	CcSEcCtD
Pomalidomide—Hypersensitivity—Zoledronate—osteoporosis	0.000115	0.000695	CcSEcCtD
Pomalidomide—Vomiting—Risedronate—osteoporosis	0.000115	0.000691	CcSEcCtD
Pomalidomide—Rash—Risedronate—osteoporosis	0.000114	0.000685	CcSEcCtD
Pomalidomide—Dermatitis—Risedronate—osteoporosis	0.000114	0.000685	CcSEcCtD
Pomalidomide—Dizziness—Pamidronate—osteoporosis	0.000113	0.000683	CcSEcCtD
Pomalidomide—Headache—Risedronate—osteoporosis	0.000113	0.000681	CcSEcCtD
Pomalidomide—Asthenia—Zoledronate—osteoporosis	0.000112	0.000677	CcSEcCtD
Pomalidomide—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000111	0.000669	CcSEcCtD
Pomalidomide—Pruritus—Zoledronate—osteoporosis	0.000111	0.000668	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Estradiol—osteoporosis	0.00011	0.000662	CcSEcCtD
Pomalidomide—Nausea—Ethinyl Estradiol—osteoporosis	0.00011	0.000662	CcSEcCtD
Pomalidomide—Insomnia—Estradiol—osteoporosis	0.000109	0.000658	CcSEcCtD
Pomalidomide—Vomiting—Pamidronate—osteoporosis	0.000109	0.000657	CcSEcCtD
Pomalidomide—Asthenia—Conjugated Estrogens—osteoporosis	0.000108	0.000652	CcSEcCtD
Pomalidomide—Rash—Pamidronate—osteoporosis	0.000108	0.000651	CcSEcCtD
Pomalidomide—Dermatitis—Pamidronate—osteoporosis	0.000108	0.000651	CcSEcCtD
Pomalidomide—Dyspnoea—Estradiol—osteoporosis	0.000108	0.000648	CcSEcCtD
Pomalidomide—Headache—Pamidronate—osteoporosis	0.000107	0.000647	CcSEcCtD
Pomalidomide—Diarrhoea—Zoledronate—osteoporosis	0.000107	0.000646	CcSEcCtD
Pomalidomide—Nausea—Risedronate—osteoporosis	0.000107	0.000645	CcSEcCtD
Pomalidomide—Pruritus—Conjugated Estrogens—osteoporosis	0.000107	0.000643	CcSEcCtD
Pomalidomide—Decreased appetite—Estradiol—osteoporosis	0.000105	0.000632	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Estradiol—osteoporosis	0.000104	0.000628	CcSEcCtD
Pomalidomide—Fatigue—Estradiol—osteoporosis	0.000104	0.000627	CcSEcCtD
Pomalidomide—Dizziness—Zoledronate—osteoporosis	0.000104	0.000624	CcSEcCtD
Pomalidomide—Constipation—Estradiol—osteoporosis	0.000103	0.000622	CcSEcCtD
Pomalidomide—Pain—Estradiol—osteoporosis	0.000103	0.000622	CcSEcCtD
Pomalidomide—Diarrhoea—Conjugated Estrogens—osteoporosis	0.000103	0.000622	CcSEcCtD
Pomalidomide—Nausea—Pamidronate—osteoporosis	0.000102	0.000614	CcSEcCtD
Pomalidomide—TNF—Cardiac Hypertrophic Response—TGFB1—osteoporosis	0.0001	0.00249	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—GPX1—osteoporosis	0.0001	0.00249	CbGpPWpGaD
Pomalidomide—Dizziness—Conjugated Estrogens—osteoporosis	9.97e-05	0.000601	CcSEcCtD
Pomalidomide—Vomiting—Zoledronate—osteoporosis	9.96e-05	0.0006	CcSEcCtD
Pomalidomide—Feeling abnormal—Estradiol—osteoporosis	9.95e-05	0.000599	CcSEcCtD
Pomalidomide—Rash—Zoledronate—osteoporosis	9.88e-05	0.000595	CcSEcCtD
Pomalidomide—Dermatitis—Zoledronate—osteoporosis	9.87e-05	0.000594	CcSEcCtD
Pomalidomide—Headache—Zoledronate—osteoporosis	9.81e-05	0.000591	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL1B—osteoporosis	9.66e-05	0.0024	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—IL1B—osteoporosis	9.66e-05	0.0024	CbGpPWpGaD
Pomalidomide—Vomiting—Conjugated Estrogens—osteoporosis	9.59e-05	0.000578	CcSEcCtD
Pomalidomide—Body temperature increased—Estradiol—osteoporosis	9.54e-05	0.000575	CcSEcCtD
Pomalidomide—Rash—Conjugated Estrogens—osteoporosis	9.51e-05	0.000573	CcSEcCtD
Pomalidomide—Dermatitis—Conjugated Estrogens—osteoporosis	9.5e-05	0.000572	CcSEcCtD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	9.45e-05	0.00235	CbGpPWpGaD
Pomalidomide—Headache—Conjugated Estrogens—osteoporosis	9.45e-05	0.000569	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—TLN1—osteoporosis	9.39e-05	0.00233	CbGpPWpGaD
Pomalidomide—TNF—TWEAK Signaling Pathway—IL6—osteoporosis	9.38e-05	0.00233	CbGpPWpGaD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	9.33e-05	0.00232	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—osteoporosis	9.32e-05	0.00232	CbGpPWpGaD
Pomalidomide—Nausea—Zoledronate—osteoporosis	9.3e-05	0.00056	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—ACTG1—osteoporosis	9.26e-05	0.0023	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—osteoporosis	9.24e-05	0.0023	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	9.15e-05	0.00228	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IRS1—osteoporosis	9.08e-05	0.00226	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	9.02e-05	0.00224	CbGpPWpGaD
Pomalidomide—Nausea—Conjugated Estrogens—osteoporosis	8.96e-05	0.00054	CcSEcCtD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—GPX1—osteoporosis	8.9e-05	0.00221	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Estradiol—osteoporosis	8.89e-05	0.000536	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—IL1B—osteoporosis	8.86e-05	0.0022	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	8.68e-05	0.00216	CbGpPWpGaD
Pomalidomide—Asthenia—Estradiol—osteoporosis	8.66e-05	0.000522	CcSEcCtD
Pomalidomide—Pruritus—Estradiol—osteoporosis	8.54e-05	0.000514	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—IGF1—osteoporosis	8.41e-05	0.00209	CbGpPWpGaD
Pomalidomide—Diarrhoea—Estradiol—osteoporosis	8.26e-05	0.000498	CcSEcCtD
Pomalidomide—TNF—Vitamin B12 Metabolism—IL6—osteoporosis	8.03e-05	0.002	CbGpPWpGaD
Pomalidomide—Dizziness—Estradiol—osteoporosis	7.98e-05	0.000481	CcSEcCtD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL1B—osteoporosis	7.88e-05	0.00196	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—osteoporosis	7.81e-05	0.00194	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP27A1—osteoporosis	7.75e-05	0.00193	CbGpPWpGaD
Pomalidomide—Vomiting—Estradiol—osteoporosis	7.68e-05	0.000462	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	7.67e-05	0.00191	CbGpPWpGaD
Pomalidomide—TNF—Transcriptional regulation of white adipocyte differentiation—TGFB1—osteoporosis	7.67e-05	0.00191	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	7.66e-05	0.0019	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP27A1—osteoporosis	7.64e-05	0.0019	CbGpPWpGaD
Pomalidomide—Rash—Estradiol—osteoporosis	7.61e-05	0.000458	CcSEcCtD
Pomalidomide—Dermatitis—Estradiol—osteoporosis	7.6e-05	0.000458	CcSEcCtD
Pomalidomide—Headache—Estradiol—osteoporosis	7.56e-05	0.000456	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—TGFB1—osteoporosis	7.51e-05	0.00187	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6R—osteoporosis	7.37e-05	0.00183	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	7.29e-05	0.00181	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	7.28e-05	0.00181	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	7.25e-05	0.0018	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—WNT1—osteoporosis	7.21e-05	0.00179	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	7.2e-05	0.00179	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	7.18e-05	0.00178	CbGpPWpGaD
Pomalidomide—Nausea—Estradiol—osteoporosis	7.17e-05	0.000432	CcSEcCtD
Pomalidomide—TNF—Apoptosis—MYC—osteoporosis	7.17e-05	0.00178	CbGpPWpGaD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—osteoporosis	7.15e-05	0.00178	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	7.14e-05	0.00178	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1B—osteoporosis	7.01e-05	0.00174	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—LEP—osteoporosis	6.8e-05	0.00169	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	6.75e-05	0.00168	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	6.68e-05	0.00166	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	6.58e-05	0.00163	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—IL6—osteoporosis	6.53e-05	0.00162	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—osteoporosis	6.25e-05	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	6.18e-05	0.00154	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL1B—osteoporosis	6.15e-05	0.00153	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	5.98e-05	0.00149	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	5.91e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	5.9e-05	0.00147	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	5.68e-05	0.00141	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1B—osteoporosis	5.61e-05	0.00139	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL1B—osteoporosis	5.48e-05	0.00136	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MYC—osteoporosis	5.46e-05	0.00136	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TGFB1—osteoporosis	5.45e-05	0.00135	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1B—osteoporosis	5.28e-05	0.00131	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	5.26e-05	0.00131	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—osteoporosis	5.21e-05	0.0013	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—IL6—osteoporosis	5.19e-05	0.00129	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	5.18e-05	0.00129	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	5.16e-05	0.00128	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—TGFB1—osteoporosis	5.04e-05	0.00125	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—IL6—osteoporosis	5.01e-05	0.00125	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	4.91e-05	0.00122	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—SOST—osteoporosis	4.87e-05	0.00121	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PKM—osteoporosis	4.87e-05	0.00121	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	4.84e-05	0.0012	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PGLS—osteoporosis	4.61e-05	0.00115	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ANTXR2—osteoporosis	4.61e-05	0.00115	CbGpPWpGaD
Pomalidomide—TNF—Toll-like Receptor Signaling Pathway—IL6—osteoporosis	4.61e-05	0.00115	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—POMC—osteoporosis	4.6e-05	0.00114	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	4.47e-05	0.00111	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—MYC—osteoporosis	4.43e-05	0.0011	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	4.42e-05	0.0011	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	4.38e-05	0.00109	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1B—osteoporosis	4.34e-05	0.00108	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL1B—osteoporosis	4.24e-05	0.00105	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—MYC—osteoporosis	4.12e-05	0.00102	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB1—osteoporosis	4.11e-05	0.00102	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL6—osteoporosis	4.1e-05	0.00102	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PKM—osteoporosis	4.08e-05	0.00101	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—FDPS—osteoporosis	4.08e-05	0.00101	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP19A1—osteoporosis	4.07e-05	0.00101	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—MYC—osteoporosis	4.06e-05	0.00101	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	4.05e-05	0.00101	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—osteoporosis	4.05e-05	0.00101	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP19A1—osteoporosis	4.01e-05	0.000998	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—osteoporosis	3.98e-05	0.000989	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GSN—osteoporosis	3.92e-05	0.000975	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPD2—osteoporosis	3.86e-05	0.000961	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PGLS—osteoporosis	3.86e-05	0.000961	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	3.82e-05	0.00095	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	3.82e-05	0.000949	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—IL6—osteoporosis	3.8e-05	0.000944	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	3.78e-05	0.00094	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—osteoporosis	3.78e-05	0.00094	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	3.72e-05	0.000925	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	3.71e-05	0.000923	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	3.71e-05	0.000921	CbGpPWpGaD
Pomalidomide—TNF—Regulation of toll-like receptor signaling pathway—IL6—osteoporosis	3.6e-05	0.000895	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	3.55e-05	0.000883	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PNP—osteoporosis	3.53e-05	0.000879	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ATIC—osteoporosis	3.53e-05	0.000879	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—LEP—osteoporosis	3.5e-05	0.000869	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LRP5—osteoporosis	3.41e-05	0.000848	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MYC—osteoporosis	3.38e-05	0.00084	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TGFB1—osteoporosis	3.37e-05	0.000837	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TGFB1—osteoporosis	3.29e-05	0.000818	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL6—osteoporosis	3.28e-05	0.000816	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LRP6—osteoporosis	3.26e-05	0.000811	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—IL6—osteoporosis	3.21e-05	0.000798	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—osteoporosis	3.15e-05	0.000782	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	3.14e-05	0.000781	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—RPL24—osteoporosis	3.14e-05	0.00078	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LTF—osteoporosis	3.14e-05	0.00078	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	3.13e-05	0.000778	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	3.1e-05	0.00077	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—osteoporosis	3.07e-05	0.000764	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—OXCT1—osteoporosis	3.01e-05	0.000747	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA2—osteoporosis	3.01e-05	0.000747	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	2.97e-05	0.000739	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6R—osteoporosis	2.93e-05	0.000729	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MGLL—osteoporosis	2.93e-05	0.000728	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—FDPS—osteoporosis	2.89e-05	0.000718	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PKM—osteoporosis	2.89e-05	0.000718	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	2.76e-05	0.000686	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PGLS—osteoporosis	2.74e-05	0.000681	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPD2—osteoporosis	2.74e-05	0.000681	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ACP5—osteoporosis	2.72e-05	0.000676	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	2.71e-05	0.000674	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—IL6—osteoporosis	2.54e-05	0.000631	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	2.53e-05	0.000629	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TPI1—osteoporosis	2.53e-05	0.000628	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ATIC—osteoporosis	2.51e-05	0.000623	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PNP—osteoporosis	2.51e-05	0.000623	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—IDH2—osteoporosis	2.49e-05	0.000619	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—POMC—osteoporosis	2.45e-05	0.000608	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—P4HB—osteoporosis	2.38e-05	0.000591	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP27A1—osteoporosis	2.34e-05	0.000582	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—GAPDH—osteoporosis	2.33e-05	0.00058	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PKM—osteoporosis	2.31e-05	0.000573	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—FDPS—osteoporosis	2.31e-05	0.000573	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.3e-05	0.000571	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.29e-05	0.00057	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ACP5—osteoporosis	2.28e-05	0.000566	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	2.25e-05	0.000559	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NFATC1—osteoporosis	2.22e-05	0.000551	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—DKK1—osteoporosis	2.2e-05	0.000547	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPD2—osteoporosis	2.19e-05	0.000544	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PGLS—osteoporosis	2.19e-05	0.000544	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.14e-05	0.000532	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA2—osteoporosis	2.13e-05	0.00053	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—OXCT1—osteoporosis	2.13e-05	0.00053	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—WNT1—osteoporosis	2.12e-05	0.000527	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TPI1—osteoporosis	2.12e-05	0.000526	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MGLL—osteoporosis	2.08e-05	0.000516	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGA—osteoporosis	2.06e-05	0.000512	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PNP—osteoporosis	2e-05	0.000497	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ATIC—osteoporosis	2e-05	0.000497	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—P4HB—osteoporosis	1.99e-05	0.000495	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GAPDH—osteoporosis	1.95e-05	0.000486	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—RAP1A—osteoporosis	1.9e-05	0.000473	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—POMC—osteoporosis	1.89e-05	0.000469	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ENO1—osteoporosis	1.84e-05	0.000457	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSMA2—osteoporosis	1.81e-05	0.00045	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—PSMA5—osteoporosis	1.81e-05	0.00045	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PKM—osteoporosis	1.78e-05	0.000443	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—FDPS—osteoporosis	1.78e-05	0.000443	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—IDH2—osteoporosis	1.77e-05	0.000439	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—TGFB1—osteoporosis	1.73e-05	0.000431	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—OXCT1—osteoporosis	1.7e-05	0.000423	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA2—osteoporosis	1.7e-05	0.000423	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PGLS—osteoporosis	1.69e-05	0.00042	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPD2—osteoporosis	1.69e-05	0.00042	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CALCA—osteoporosis	1.69e-05	0.000419	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	1.66e-05	0.000413	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP27A1—osteoporosis	1.66e-05	0.000413	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MGLL—osteoporosis	1.66e-05	0.000412	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	1.63e-05	0.000405	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	1.62e-05	0.000404	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ACP5—osteoporosis	1.61e-05	0.000401	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	1.56e-05	0.000388	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ATIC—osteoporosis	1.54e-05	0.000384	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PNP—osteoporosis	1.54e-05	0.000384	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ENO1—osteoporosis	1.54e-05	0.000382	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—KL—osteoporosis	1.53e-05	0.000381	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	1.52e-05	0.000378	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	1.52e-05	0.000377	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSMA5—osteoporosis	1.52e-05	0.000377	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—PSMA2—osteoporosis	1.52e-05	0.000377	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TPI1—osteoporosis	1.5e-05	0.000373	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—P4HB—osteoporosis	1.41e-05	0.000351	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—IDH2—osteoporosis	1.41e-05	0.00035	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GAPDH—osteoporosis	1.39e-05	0.000344	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—RAP1A—osteoporosis	1.35e-05	0.000335	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP27A1—osteoporosis	1.32e-05	0.000329	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA2—osteoporosis	1.31e-05	0.000326	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—OXCT1—osteoporosis	1.31e-05	0.000326	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—IL6—osteoporosis	1.31e-05	0.000325	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ACP5—osteoporosis	1.29e-05	0.00032	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MGLL—osteoporosis	1.28e-05	0.000318	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	1.27e-05	0.000316	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP19A1—osteoporosis	1.23e-05	0.000306	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—ADCY5—osteoporosis	1.2e-05	0.000298	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TPI1—osteoporosis	1.2e-05	0.000298	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—P4HB—osteoporosis	1.13e-05	0.00028	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GAPDH—osteoporosis	1.11e-05	0.000275	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—osteoporosis	1.1e-05	0.000274	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ENO1—osteoporosis	1.09e-05	0.000271	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—IDH2—osteoporosis	1.09e-05	0.00027	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—RAP1A—osteoporosis	1.08e-05	0.000268	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSMA5—osteoporosis	1.07e-05	0.000267	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PSMA2—osteoporosis	1.07e-05	0.000267	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IRS2—osteoporosis	1.05e-05	0.000261	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.02e-05	0.000254	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ADCY5—osteoporosis	1e-05	0.00025	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GPX1—osteoporosis	1e-05	0.000249	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ACP5—osteoporosis	9.95e-06	0.000247	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—POMC—osteoporosis	9.39e-06	0.000233	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TPI1—osteoporosis	9.25e-06	0.00023	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—osteoporosis	9.24e-06	0.00023	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IRS1—osteoporosis	9.16e-06	0.000228	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP19A1—osteoporosis	8.72e-06	0.000217	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ENO1—osteoporosis	8.71e-06	0.000216	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—P4HB—osteoporosis	8.69e-06	0.000216	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6R—osteoporosis	8.61e-06	0.000214	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSMA2—osteoporosis	8.58e-06	0.000213	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PSMA5—osteoporosis	8.58e-06	0.000213	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GAPDH—osteoporosis	8.53e-06	0.000212	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—RAP1A—osteoporosis	8.31e-06	0.000207	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—POMC—osteoporosis	7.39e-06	0.000184	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ADCY5—osteoporosis	7.12e-06	0.000177	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GPX1—osteoporosis	7.1e-06	0.000176	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP19A1—osteoporosis	6.96e-06	0.000173	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ENO1—osteoporosis	6.72e-06	0.000167	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSMA5—osteoporosis	6.62e-06	0.000165	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PSMA2—osteoporosis	6.62e-06	0.000165	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—osteoporosis	6.55e-06	0.000163	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ADCY5—osteoporosis	5.69e-06	0.000141	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GPX1—osteoporosis	5.67e-06	0.000141	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP19A1—osteoporosis	5.37e-06	0.000134	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—POMC—osteoporosis	5.24e-06	0.00013	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—osteoporosis	5.23e-06	0.00013	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MYC—osteoporosis	5.1e-06	0.000127	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—TGFB1—osteoporosis	5.09e-06	0.000127	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ADCY5—osteoporosis	4.39e-06	0.000109	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GPX1—osteoporosis	4.37e-06	0.000109	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—POMC—osteoporosis	4.18e-06	0.000104	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—osteoporosis	4.04e-06	0.0001	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—IL6—osteoporosis	3.84e-06	9.53e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—POMC—osteoporosis	3.23e-06	8.02e-05	CbGpPWpGaD
